{"nctId":"NCT03065244","briefTitle":"KIDCARE (Kawasaki Disease Comparative Effectiveness Trial)","startDateStruct":{"date":"2017-02-17","type":"ACTUAL"},"conditions":["Mucocutaneous Lymph Node Syndrome"],"count":105,"armGroups":[{"label":"IVIG","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: IVIG"]},{"label":"Infliximab","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Infliximab"]}],"interventions":[{"name":"IVIG","otherNames":["Intravenous immunoglobulin"]},{"name":"Infliximab","otherNames":["Remicade"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Eligible subjects will be as follows:\n\n  1. 4 weeks to 17 years of age,\n  2. fulfill the American Heart Association case definition for complete or incomplete KD,\n  3. have had fever (T ≥38°C) for 3 to 10 days prior to initial IVIG treatment,\n  4. have fever (T ≥38°C orally or rectally) between 36 hours and 7 days after end of the first IVIG infusion without other likely cause\n\nExclusion Criteria:\n\n1. Patient treated with infliximab or steroids for present illness (pts who received oral steroids as outpatients prior to KD diagnosis but who otherwise qualify for the study will not be excluded)\n2. Known prior infection with tuberculosis, coccidiomycosis, or histoplasmosis.","healthyVolunteers":false,"sex":"ALL","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Cessation of Fever Within 24h of Initiation of Study Treatment With no Fever Recurrence Within Next 7 Days.","description":"A fever will be considered ≥38°C rectally or orally and ≥ 37.5°C axillary. Cessation of fever within 24h of initiation of study treatment with no fever recurrence within next 7 days.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in White Blood Cell Count (WBC) Between Baseline and 24 Hours and 2 Weeks Following Study Treatment.","description":"Change in white blood cell count (WBC), between baseline and 24 hours and 2 weeks following study treatment.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.05","spread":null},{"groupId":"OG001","value":"0.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.9","spread":null},{"groupId":"OG001","value":"-3.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Zworst Score Between Baseline and 2-week (± 4 Days) Echocardiograms","description":"Zworst score is defined as the largest internal diameter of either the right coronary or left anterior descending arteries normalized for body surface area and expressed as standard deviation units from the mean. A Z-score \\>= 2.5 is considered a aneurysm according to the American Heart Association criteria.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.31","spread":null},{"groupId":"OG001","value":"-0.01","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Number of Fever Days (24 Hour Period With a T≥38.0°C) From Enrollment","description":"Determine the number of days a participant had a fever once the participant has been enrolled into the study.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Hospitalization","description":"How long a participant was hospitalized for.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With IVIG and Infliximab Infusion Reactions and Complications","description":"Determine any complications and/or reactions to each treatment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Absolute Neutrophil Count (ANC) Between Baseline and 24 Hours and 2 Weeks Following Study Treatment.","description":"Change in absolute neutrophil count (ANC) between baseline and 24 hours and 2 weeks following study treatment.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3398.4","spread":null},{"groupId":"OG001","value":"-1742","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5853.5","spread":null},{"groupId":"OG001","value":"-4661.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in C-reactive Protein (CRP, mg/dL) Concentration Between Baseline and 24 Hours and 2 Weeks Following Study Treatment.","description":"Change in C-reactive protein (CRP, mg/dL) concentration between baseline and 24 hours and 2 weeks following study treatment.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.6","spread":null},{"groupId":"OG001","value":"-4.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.6","spread":null},{"groupId":"OG001","value":"-13.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":27,"n":49},"commonTop":["Fever after discharge not attributed to KD","GI Symptoms","Rash","Arthritis/pain and swelling in extremities","Epistaxis"]}}}